HAR DU LYST TIL Å VÆRE REDAKSJONSMEDLEM I KIRURGEN?

Vi ønsker oss en medarbeider som arbeider som kirurg/ortoped, liker å holde seg oppdatert, gjerne leser korrektur og har gode ideer til nyttig innhold for hele landets kirurger. Det er viktig at du liker å arbeide i team og det er en fordel dersom du har skrevet fagartikler tidligere. Send meg gjerne en mail innen 15. april 2023 dersom dette treffer deg.

Marte Bliksøen (redaktør) marte@kirurgen.no

S 10: KREFT I MAGESEKKEN – FOREKOMST, ETIOLOGI OG OVERLEVELSE

1. Ferlay J, Ervik M, Lam, F et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. https://gco.iarc.fr/today.

2. Cancer Registry of Norway. Cancer in Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway, 2022.

3 Wroblewski LE, Peek RM Jr. Helicobacter pylori. Cancer, and the Gastric Microbiota. Adv Exp Med Biol. 2016; 908:393-408.

4. Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 2015; 137: 598-606.

5. https://www.helsebiblioteket.no/.../kreft-i-magesekken–handlingsprogram

6. Lauren, P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta pathol et Microbiol Scand 1965;64: 31-49.

7. Viste A, Eide GE, Halvorsen K et al. The prognostic value of Lauren’s histopathological classification system and ABO blood groups in patients with stomach carcinoma. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the Br Surg Oncol. 1986; 12: 135-141.

8. Årsrapport 2020 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for kreft i spiserør og magesekk. Oslo: Kreftregisteret, 2021. ISBN 978-82-473-01012.

9. Bringeland EA, Wasmuth HH, Fougner R et al. Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. Br J Surg. 2014; 101: 1712-20.

10. Cunningham D, Allum WH, Stenning SP et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.

11. Al-Batran SE, Homann N, Pauligk C et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393: 1948-1957.

12. Songun I, Putter H, Kranenbarg EM et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11: 439-49.

13. Reim D, Loos M, Vogl F et al. Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol. 2013; 31: 263-71

S12: ADENOKARSINOMER I DEN GASTROØSOFAGEALE OVERGANG

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65: 87-108.

2. Aahlin EK, Olsen F, Uleberg B, et al. Major postoperative complications are associated with impaired long-term survival after gastro-esophageal and pancreatic cancer surgery: a complete national cohort study. BMC Surg. 2016; 16:32.

3. Cancer Genome Atlas Research Network; Analysis Working Group. Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541:169-175.

4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202-9.

5. Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021; 384: 1191-1203.

6. Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393: 1948-1957.

7. van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366:2074-84.

8. Nasjonalt handlingsprogram for kreft i spiserør. Helsedirektoratet 2022

9. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology. 2006; 131: 1392-9.

S 16: ENDOSKOPISK BEHANDLING AV VENTRIKKELCANCER

1. Helsedirektoratet. Kreft i magesekken – handlingsprogram 2021 [updated 28.09.2021. Available from: https://www.helsedirektoratet.no/retningslinjer/kreft-i-magesekken-handlingsprogram.

2. Everett SM, Axon AT. Early gastric cancer in Europe. Gut. 1997;41(2):142-50.

3. Kreftregisteret. Statistikkbank [Available from: https://sb.kreftregisteret.no/insidens/.

4. Pimentel-Nunes P, Libânio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022;54(6):591-622.

5. Wang S, Zhang Z, Liu M, Li S, Jiang C. Endoscopic Resection Compared with Gastrectomy to Treat Early Gastric Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(12):e0144774.

6. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3(4):219-25.

7. Shi D, Xi XX. Factors Affecting the Accuracy of Endoscopic Ultrasonography in the Diagnosis of Early Gastric Cancer Invasion Depth: A Meta-analysis. Gastroenterol Res Pract. 2019;2019:8241381.

8. Park YM, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011;25(8):2666-77.

9. Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc. 2012;76(4):763-70.

S 18: PERIOPERATIV ONKOLOGISK BEHANDLING FOR KREFT I MAGESEKKEN

1. Kreftregisteret. Årsrapport 2020 - Resultater og forbedringstiltak fra kvalitetsregister for kreft i spiserør og magesekk https://www.kreftregisteret.no/globalassets/ publikasjoner-og-rapporter/arsrapporter/publisert-2021/arsrapport-kvalitetsregister-for-kreft-i-spiseror-og-magesekk-2020.pdf2021 [

2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.

3. Holmebakk T, Frykholm G, Viste A, Norwegian Gastrointestinal Cancer G. Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit. Eur J Surg Oncol. 2010; 36: 610-6.

4. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019; 393: 1948-57.

5. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-30.

6. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012; 30: 268-73.

7. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19: 616-28.

8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357: 1810-20.

9. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379: 315-21.

10. Kakeji Y, Yoshida K, Kodera Y, et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022; 25: 188-96.

11. Kang YK, Yook JH, Park YK, et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39: 2903-13.

12. Zhang X, Liang H, Li Z, Xue Y, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021; 22: 1081-92.

13. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-97.

14. Hofheinz RD, Merx K, Haag GM, et al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022; 40: 3750-61.

15. Pietrantonio F, Miceli R, Raimondi A, et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019; 37: 3392-400.

16. Al-Batran S-E. Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. Ann Oncol. 2020; 31: S927-S8.

17. Cercek A. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. Journal of Clinical Oncology. 2022.

18. Chalabi M. Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann Oncol. 2022;33.

19. Andre T, Tougeron D, Piessen G, et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2022:JCO2200686.

S 21 RESPONSEVALUERING ETTER NEOADJUVANT KJEMOTERAPI VED VENTRIKKELKREFT – HVORFOR, HVORDAN OG HVA FORTELLER DET OSS EGENTLIG?

1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England journal of medicine. 2006;355(1):11-20.

2. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet (London, England). 2019;393(10184):1948-57.

3. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA oncology. 2017;3(9):1197-203.

4. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680-6.

5. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-30.

6. Salmanoglu E. The role of [18F]FDG PET/CT for gastric cancer management. Nucl Med Rev Cent East Eur. 2021;24(2):99-103.

7. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107-16.

8. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2009;12(1):6-22.

9. Sandø AD, Fougner R, Grønbech JE, Bringeland EA. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World J Surg Oncol. 2021;19(1):212.

10. Gertsen EC, de Jongh C, Brenkman HJF, Mertens AC, Broeders I, Los M, et al. The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer. Eur J Surg Oncol. 2020;46(7):1247-53.

11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45(2):228-47.

12. Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C, et al. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med. 2022;20(1):107.

13. Li Z, Wang Y, Ying X, Shan F, Wu Z, Zhang L, et al. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer. 2019;19(1):80.

14. Rice TW, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, et al. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Dis Esophagus. 2016;29(7):715-23.

15. Prasad P, Sivaharan A, Navidi M, Fergie BH, Griffin SM, Phillips AW. Significance of neoadjuvant downstaging in gastric adenocarcinoma. Surgery. 2022.

16. Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, et al. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Ann Surg Oncol. 2020;27(9):3182-92.

17. Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32(27):2983-90.

18. Klevebro F, Tsekrekos A, Low D, Lundell L, Vieth M, Detlefsen S. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus. 2020;33(6).

19. Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607-16.

20. Lombardi PM, Mazzola M, Achilli P, Aquilano MC, De Martini P, Curaba A, et al. Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience. Journal of surgical oncology. 2021;123(4):923-31.

S 24: ROBOTASSISTERT MINIMAL INVASIV GASTREKTOMI – KEISERENS

NYE KLÆR ELLER OPTIMALISERING AV KIRURGISK TEKNIKK?

1. Mala T, Førland D, Skagemo C, et al. Early experience with total robotic D2 gastrectomy in a low incidence region: surgical perspectives. BMC Surg 2022; 22: 137.

2. Kitano S, Iso Y, Moriyama M, et al. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994; 4: 146-8.

3. Shi Y, Xu X, Zhao Y, et al. Short-term surgical outcomes of a randomized controlled trial comparing laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc 2018; 32: 2427-33.

4. Park YK, Yoon HM, Kim YW, et al. Laparoscopy-assisted versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: Results From a Randomized Phase II Multicenter Clinical Trial (COACT 1001). Ann Surg 2018; 267: 638-45.

5. van der Veen A, Brenkman HJF, Seesing MFJ, et al. Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial. J Clin Oncol 2021; 39: 978-89.

6. Hyung WJ, Yang HK, Park YK, et al. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol 2020; 38: 3304-13.

7. Hashizume M, Shimada M, Tomikawa M, et al. Early experiences of endoscopic procedures in general surgery assisted by a computer-enhanced surgical system. Surg Endosc 2002; 16: 1187-91.

8. Strong VE, Russo AE, Nakauchi M, et al. Robotic gastrectomy for gastric adenocarcinoma in the USA: insights and oncologic outcomes in 220 patients. Ann Surg Oncol. 2021;28:742–50

9. Kim MS, Kim WJ, Hyung WJ, et al. Comprehensive Learning Curve of Robotic Surgery: Discovery From a Multicenter Prospective Trial of Robotic Gastrectomy. Ann Surg 2021; 273: 949-56.

10. Zheng-Yan L, Feng Q, Yan S, et al. Learning curve of robotic distal and total gastrectomy. Br J Surg 2021; 108: 1126-32.

11. Huang Y, Pan M, Chen B. A Systematic Review and Meta-Analysis of Sentinel Lymph Node Biopsy in Gastric Cancer, an Optimization of Imaging Protocol for Tracer Mapping. World journal of surgery 2021; 45: 1126-34.

12. Marano L, Fusario D, Savelli V, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: an umbrella review of systematic reviews and meta-analyses. Updates Surg 2021; 73: 1673-89.

13. Guerrini GP, Esposito G, Magistri P, et al. Robotic versus laparoscopic gastrectomy for gastric cancer: The largest meta-analysis. International journal of surgery (London, England) 2020; 82: 210-28.

14. Ojima T, Nakamura M, Hayata K, et al. Short-term Outcomes of Robotic Gastrectomy vs Laparoscopic Gastrectomy for Patients With Gastric Cancer: A Randomized Clinical Trial. JAMA Surg 2021; 156: 954-63.

15. Lu J, Zheng CH, Xu BB, et al. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial. Ann Surg 2021; 273: 858-67.

16. Baral S, Arawker MH, Sun Q, et al. Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: A Mega Meta-Analysis. Front Surg 2022; 9: 895976.

17. Mala T, Johannessen HO, Førland D, et al. [Laparascopic resection for gastric cancer at Oslo University Hospital, Ullevål 2015–18]. Tidsskr Nor Laegeforen 2018; 138.

18. Bobo Z, Xin W, Jiang L, et al. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: meta-analysis and trial sequential analysis of prospective observational studies. Surg Endosc 2019; 33: 1033-48.

19. Chen K, Pan Y, Zhang B, et al. Robotic versus laparoscopic Gastrectomy for gastric cancer: a systematic review and updated meta-analysis. BMC Surg 2017; 17: 93.

S 30: INTRAPERITONEAL KJEMOTERAPI VED PERITONEAL KARSINOMATOSE FRA VENTRIKKELCANCER

1. Koemans WJ, Lurvink RJ, Grootscholten C et al. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer 2021; 24: 800–809.

2. Hultman B, Gunnarsson U, Nygren P et al. Prognostic factors in patients with locoregionally advanced gastric cancer. World J Surg Oncol 2017; 15: 172.

3. Mokadem I, Dijksterhuis WPM, van Putten M et al. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer 2019; 22: 1263–1273.

4. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003; 14: 1705–1713.

5. Ceelen W, Braet H, van Ramshorst G et al. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert opinion on drug delivery. 2020, VOL. 17, NO.4, 511–522.

6. van Baal JOAM, Van de Vijver KK, Nieuwland R et al. The histophysiology and pathophysiology of the peritoneum. Tissue and Cell 2017; 49: 95–105.

7. Yonemura Y, Ishibashi H, Mizumoto A et al. The Development of Peritoneal Metastasis from Gastric Cancer and Rationale of Treatment According to the Mechanism. J Clin Med 2022; 17; 11: 458.

8. Chia CS, You B, Decullier E et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol 2016; 23: 1971–1979.

9. Lordick F. Carneiro F, Cascinu S al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Volume 33 - Issue 10 – 2022.

10. Ajani JA, D’Amico TA, Bentrem DJ et al. Gastric Cancer, Version 2.2022. JNCCN.org Volume 20 Issue 2 February 2022.

11. Valetti M, Eshmuminov D, Gnecco N et al. Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World J Surg Oncol 2021; 19:245.

12. Fushida S, Kinoshita J, Kaji M et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013; 71; 1265-1272.

13. Zhuang X, He Y, Ma W. Prophylactic hyperthermic intraperitoneal chemotherapy may benefit the longterm survival of patients after radical gastric cancer surgery. Scientific Reports | 2022; 12:2583.

14. Leake P-A, Cardoso R, Seevaratnam R et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012; 15 (SUPPL.1), pp. S27-S37.

15. Hübner M, Alyami M, Villeneuve L et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. Eur J Surg Oncol 2022; 48: 789e794.

16. Solass W, Hetzel A, Nadiradze G et al Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 2012; 26: 1849–1855.

17. Bellendorf, A, Khosrawipour V, Khosrawipour T et al. Scintigraphic peritoneography reveals a non-uniform 99, Tc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model. Surg Endosc 2018; 32: 166–174.

18. RahimiGorji M, Debbaut C, Ghorbaniasl G et al. Optimization of intraperitoneal aerosolized drug delivery using computational fluid dynamics (CFD) modeling. Scien Reports 2022; 12:6305.

19. Caspers IA, Sikorska K, Slagter AE et al. Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial. Cancers 2021; 13: 4626.

20. Tavernier C, Passot G, Vassal O et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: an experimental study. Surg Endosc 2020; 34: 2939–2946.

Vårmøte 27-28 april 2023

NGICG og NFGK inviterer til:

OnkoKirurgisk Vårmøte 2023

Vi presenterer et spennende, tverrfaglig program med nyheter, oppdateringer og aktuelle diskusjoner for diagnostikk og behandling på kreftområdet. Programmet spenner over hele gastrointestinal trakten og er tverrfaglig sammensatt. ***

Vi ser frem til sosial sammenkomst og hyggelig festmiddag på torsdags kveld. ***

Vi inviterer spesielt alle unge leger til å delta, spesielt nåværende eller vordende PhD studenter, og alle med interesse til å delta på det nye initiativet for forskningserfaring og diskusjon i « NGICG akademiet» på torsdags formiddag! ***

Vi satser på full t hus som i 2022! Deltagelse følger etter ‘først til mølla’ prinsippet da det er begrenset med plas ser: Lenke til påmelding og hotellbestilling vil følge snarlig på hjemmesiden www.ngicg.no

***

På vegne av arrangørene ønskes velkommen til et supert fagmøte!

Kjetil Søreide

Leder, NGICG

NGICG akademiet, torsdag 27. april 09:00 – 13:00:

Presentasjoner på aktuelle forskningstema med diskusjoner, bl.a:

• Valg av studiedesign – fordeler og ulemper fra registerdata til randomisert studie (Sheraz Yaqub, OUS)

• Hva er EQUATOR? Retningslinjer og maler i studieoppsett og presentasjon (Kenneth Thorsen, SUS)

• Fra idé til publikasjon i Nature Medicine – tips og personlige erfaringer (John Amund Kyte, OUS)

• Databasen i prosjektet – byggetrinn, huskeregler og fallgruver (Kristoffer Brudvik, OUS)

• Responsevaluering av kreftbehand ling – typer grafer, kurver og fortolkning (Kristine Aakre, HUS)

• Overlevelseskurver – tips og fallgruver i presentasjon og fortolkning (Dyre Kleive, OUS)

• Presentasjonsteknikk – kjernekunnskap og nyttige tips (Åsmu nd Fretland, OUS)

• Fra ide til New Englan d Journal of Medicine – tips og personlig erfaring (Michael Bretthauer, OUS)

• «Visual abstracts – hva er det?» TBA

• «Sosiale media – nyttig eller tidtrøyte?» TBA

• «Rejected paper – hva nå og hvordan?» TBA

Se kirurgen.no for program